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INTRODUCTION
This chapter will focus on the treatment of HSP nephritis
in adults and children. The cost implications for global
application of this guideline are addressed in Chapter 2.
11.1: Treatment of HSP nephritis in children
11.1.1: We suggest that children with HSP nephritis
and persistent proteinuria,40.5-1g/d per 1.73m2,
are treated with ACE-I or ARBs. (2D)
11.1.2: We suggest that children with persistent
proteinuria, 41 g/d per 1.73m2, after a trial
of ACE-I or ARBs, and GFR 450ml/min per
1.73m2, be treated the same as for IgAN with a
6-month course of corticosteroid therapy (see
Chapter 10). (2D)
11.2: Treatment of crescentic HSP nephritis in children
11.2.1: We suggest that children with crescentic HSP
with nephrotic syndrome and/or deterio-
rating kidney function are treated the same
as for crescentic IgAN (see Recommendation
10.6.3). (2D)
BACKGROUND
HSP is an acute small-vessel vasculitis, characterized clinically
by a nonthrombocytopenic purpuric rash, nondeforming
arthritis, gastrointestinal involvement, and nephritis.554 The
incidence of HSP is about 10 cases per 100,000 per year.
It affects all ages, but 90% of cases are found in those less
than 10 years of age, with the median age at presentation
being 6 years.554 Kidney involvement occurs in 30-50%
patients.554–556 Microscopic hematuria is the most common
finding. In a systematic review of 12 studies of 1133
unselected children with HSP, abnormal urinalysis occurred
in 34% with the majority (79%) having isolated hematuria
with or without proteinuria.555 Only 21% of those with
kidney involvement (or 7.2% of all cases) developed a
nephritic and/or nephrotic syndrome. Ninety percent of
children had developed kidney involvement by 8 weeks after
acute presentation, while 97% developed kidney involvement
by 6 months. Recurrence of rash and other symptoms occur
in one-third of patients.556 Nephritis is associated with older
age at presentation, persistent rash, and recurrence of HSP,
while proteinuria 420 mg/m2/h was associated with recur-
rence and severe abdominal pain.557 Only 1-3% of patients
progress to ESRD.554 Long-term prognosis correlates with
kidney presentation at onset. Compared to 1.6% of children
with isolated hematuria with/without proteinuria, 19.5% of
children with nephritic or nephrotic syndromes at initial
presentation have nephrotic-range proteinuria, hypertension,
and/or reduced GFR at long-term follow up.555 Among 78
patients managed in specialized pediatric kidney units, 44%
of those with a nephritic or nephrotic presentation had
hypertension and/or impaired kidney function at a mean
follow-up of 23.4 years, while 82% of those presenting with
hematuria with or without proteinuria had normal urina-
lysis, kidney function, and blood pressure.558 A recent study
of 103 children found that, at final follow up, GFR correlated
with GFR and proteinuria at onset and 1 year, with ISKDC
pathology grade and interstitial fibrosis. Multivariate analysis
identified that proteinuria at 1 year and ISKDC grade were
most useful in identifying patients with a poor prognosis.559
However, one long-term study found that severity of findings
on first kidney biopsy did not correlate with the risk of a poor
outcome (hypertension, persistent proteinuria, ESRD).560
RATIONALE
K There is no evidence for the use of RAS blockade in HSP
nephritis in children, but an RCT in children and young
adults with IgAN demonstrated the benefit of this
therapy in reducing proteinuria and maintaining GFR.
K There is no evidence for the use of oral corticosteroids in
HSP nephritis, but data from RCTs in adults with IgAN
have demonstrated a benefit in reducing proteinuria and
maintaining GFR.
K There is very low–quality evidence for the benefit of high-
dose corticosteroids and immunosuppressive agents in
HSP nephritis with deteriorating kidney function.
There is no evidence available for the use of RAS blockade
in HSP nephritis. However, an RCT in 66 children and
young adults with IgAN with moderate proteinuria (41 to
o3.5 g/d per 1.73 m2) and GFR 450 ml/min per 1.73 m2
demonstrated the benefit of ACE-I in reducing proteinuria
and maintaining GFR.478 There are very limited data to
support the use of corticosteroids in children with established
nephritis of any severity,561 though corticosteroids are widely
used in children presenting with nephrotic-range proteinuria
or acute nephritis. In a post-hoc analysis of one placebo-
controlled RCT,562 nephritis resolved more rapidly in
children treated with prednisone compared to placebo. Seven
of 36 children (19%) in the prednisone group still had kidney
involvement at 6 months compared to 15 of 35 (43%) in the
placebo group. The trial only provided outcome data to
6 months after randomization, so it is unclear whether
prednisone treatment reduced the number of patients with
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persistent HSP nephritis overall, or promoted more rapid
resolution of kidney disease compared to placebo.
A prospective but uncontrolled study of 38 consecutive
children with mean follow-up period of 5 years and 7 months
showed resolution of severe nephritis (nephrotic syndrome
and/or 450% crescents on biopsy) in 27 of 38 children
treated with three pulses of methylprednisolone followed by
oral prednisone for 4 months.563 Seven children had residual
abnormalities and four progressed to ESRD. Two recent RCTs
in adults with IgAN, proteinuria Z1 g/d, and GFR Z30-
50 ml/min per 1.73 m2 have demonstrated the benefit of 6-8
months of prednisone and ACE-I, compared to ACE-I alone,
on reducing the rate of kidney functional deterioration and
reducing proteinuria during follow-up periods of up to
48 months511 or 96 months.510
In the absence of sufficient long-term data in HSP
nephritis, we suggest that persistent HSP nephritis can be
treated as isolated IgAN (see Recommendation 10.3.1).
However, there are no data to determine when prednisone
should be commenced in children with HSP nephritis, and
for how long ACE-I or ARB therapy should be administered
before commencing prednisone. Foster et al.564 noted that
the chronicity score (interstitial fibrosis, tubular atrophy,
fibrosed crescents) on initial kidney biopsy increased with
increasing delay between onset of kidney involvement and
time of biopsy. Most children in their series of 20 patients
were biopsied within 3 months, with a median of 30 days.
Treatment with prednisone and azathioprine resulted in
improvement in acuity score but not chronicity score.
Therefore, in HSP nephritis, it may be appropriate to
commence prednisone therapy earlier than in IgAN.
There are limited data on immunosuppressive agents, so it
remains unclear whether these have any role in HSP
nephritis. In a single RCT of 56 children with significant
HSP nephritis (nephrotic range proteinuria, reduced kidney
function, ISKDC* grades III–V on kidney biopsy [crescents
o50% to 475%]) treated within 3 months of onset of HSP
and followed for 5-6 years, there was no significant difference
in the risk for persistent kidney involvement of any severity
between cyclophosphamide and supportive treatment (RR
1.07; 95% CI 0.65-1.78).565 Corticosteroids were not
administered to these children. A nonrandomized compara-
tive study of 37 children with HSP nephritis and 450%
crescents (ISKDC grades IV-V) on kidney biopsy found that
none of 17 treated with cyclophosphamide plus corticoster-
oids, compared to four of 20 treated with corticosteroids
alone, had persistent nephropathy (proteinuria 420 mg/m2/h
with/without GFR o40 ml/min per 1.73 m2) at 6-8 years of
follow-up.566 A small RCT, in children with nephrotic-range
proteinuria and/or ISKDC grades III-V on kidney biopsy,
found that all of 10 children treated with cyclosporin achieved
remission compared to five of nine children treated with
methylprednisolone.567 However, at the 2-year follow-up of
23 children, seven of 11 children treated with cyclosporin and
seven of 12 treated with methylprednisolone had persistent
proteinuria with/without decreased GFR.568
One nonrandomized comparative study involving 20
children with nephrotic-range proteinuria and ISKDC grades
II-III on kidney biopsy reported that none of 10 children
treated with azathioprine and prednisone, compared to four
of 10 treated with prednisone alone, had nephrotic-range
proteinuria and/or GFR o60 ml/min per 1.73 m2 after 4-5
years of follow-up.569 Observational studies have reported
good outcomes with corticosteroids combined with
azathioprine,564 cyclophosphamide,570 cyclosporine,571,572
and plasma exchange.573,574 There are no data, other than
small observational studies, examining the treatment of
crescentic HSP nephritis with rapidly progressive kidney
failure. In the absence of data, we suggest treating such
patients similarly to patients with ANCA vasculitis.
A single small RCT575 comparing 1 year of treatment with
MMF to azathioprine has enrolled 17 children (ISKDC grade
II and III) to date. Proteinuria resolved in all of 10 children
treated with MMF, and six of eight treated with azathioprine.
Seven patients treated with MMF and five treated with
azathioprine showed regression of histological changes at
1 year. Children received prednisone for 6 months, but were
not treated with ACE-I. These data are insufficient to draw
any conclusions on the value of MMF in HSP nephritis in
children.
11.3: Prevention of HSP nephritis in children
11.3.1: We recommend not using corticosteroids to
prevent HSP nephritis. (1B)
BACKGROUND
At first presentation with HSP, nephritis may be clinically
mild or even absent. Therefore, treatment strategies at the
time of presentation have been developed with the goal of
preventing nephritis, or reducing the risk of severe persistent
nephritis.
RATIONALE
K There is moderate-quality evidence to recommend that
corticosteroids not be given at presentation of HSP, since
they do not appear to influence the development of
persistent kidney involvement.
A meta-analysis576,577 of five RCTs (789 children) found no
significant difference in the number of children with evidence
of persistent kidney disease (microscopic hematuria, protei-
nuria, hypertension, reduced kidney function) during follow-
up between those treated with prednisone for 2-4 weeks and
those not treated (RR 0.73; 95% CI 0.43-1.24). There were no
significant differences in the risk of persistent kidney disease
at 6 months (379 children; RR 0.54; 95% CI 0.25-1.18) and
12 months (498 children; RR 1.02; 95% CI 0.40-2.62). Three
of the five trials (568 patients) were well designed, placebo-
controlled trials; exclusion of poor-quality studies from the
*The histological classification of HSP nephritis proposed by the Interna-
tional Study of Kidney Disease in Children is still widely used.
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meta-analysis removed heterogeneity without altering the
findings. Two RCTs562,578 found no significant difference in
the risk of severe nephritis (nephrotic-range protein-
uria, hypertension with/without reduced kidney function)
between children treated with prednisone or placebo at
presentation, though the number of events was small,
resulting in imprecision (261 children; RR 1.92; 95% CI
0.57-6.50). There are no data on prevention strategies for
HSP nephritis in adults.
11.4: HSP nephritis in adults
11.4.1: We suggest that HSP nephritis in adults be
treated the same as in children. (2D)
RATIONALE
Outcome data from HSP nephritis in adults are from
retrospective series. A Spanish retrospective study of HSP
in adults suggested a higher frequency of kidney involvement
than children, but the final outcome of HSP is equally good
in patients of both age groups.579 In an Italian cohort, the
risk for progression of HSP nephritis was found greater in
adults and was associated with increasing proteinuria during
follow-up.580 In a UK series, the risk factors for ESRD
were: proteinuria Z1 g/d during follow-up, hypertension at
presentation and during follow-up, kidney impairment at
presentation—very similar to the prognostic indicators in
IgAN in adults.581
In a Finnish series, kidney survival 10 years after biopsy
was 91%.582 A recent cohort of HSP nephritis in Chinese
adults showed a higher risk of progression to kidney
impairment compared to children.583 The biggest retro-
spective cohort of 250 adults with HSP was from France.584
After a median follow-up of 14.8 y, 32% of the patients
showed kidney impairment (CrCl o50 ml/min), usually
associated with proteinuria and/or hematuria.
There are very few RCTs investigating the treatment of
HSP nephritis in adults. A recent 12-month, multicenter,
prospective, open-label trial (CESAR study) was performed
using steroid therapy without or with cyclophosphamide in
54 adults with severe HSP including proliferative GN and
severe visceral manifestations.585 The study did not include
patients with rapidly progressive GN. All patients received
steroids while 25 were randomized to also receive cyclopho-
sphamide. There was no additional benefit of cyclopho-
sphamide compared to steroids alone. The investigators
commented that the small population size did not permit
definitive conclusions.
We suggest that treatment for HSP nephritis in adults
should use the approach proposed for HSP in children (see
Sections 11.1 and 11.2). Current evidence does not suggest
using additional immunosuppressive agents other than
steroids in HSP nephritis in adults.
RESEARCH RECOMMENDATIONS
K An RCT comparing a 6- to 12-month course of cortico-
steroids to shorter-duration corticosteroids (28 days)
should be performed in children with moderately severe
HSP nephritis (acute nephritic syndrome or nephrotic
syndrome with normal kidney function and o50%
crescents or sclerosing lesions on biopsy).
K RCTs are required to determine whether immuno-
suppressive agents (cyclosporine, azathioprine, MMF)
and corticosteroids are effective in treating children with
severe HSP nephritis (acute nephritic syndrome, nephro-
tic syndrome with or without reduced kidney function
with 450% crescents or sclerosing lesions on biopsy).
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